Cogentix Medical (NASDAQ: CGNT) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare Cogentix Medical to related companies based on the strength of its risk, analyst recommendations, institutional ownership, valuation, profitability, dividends and earnings.
Risk and Volatility
Cogentix Medical has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Cogentix Medical’s peers have a beta of 0.89, indicating that their average share price is 11% less volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Cogentix Medical and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cogentix Medical Competitors||416||2179||3383||122||2.53|
As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 21.58%. Given Cogentix Medical’s peers higher possible upside, analysts clearly believe Cogentix Medical has less favorable growth aspects than its peers.
Institutional & Insider Ownership
12.7% of Cogentix Medical shares are held by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 35.5% of Cogentix Medical shares are held by insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Cogentix Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cogentix Medical Competitors||-330.24%||-33.51%||-12.50%|
Earnings & Valuation
This table compares Cogentix Medical and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cogentix Medical||$53.65 million||$3.20 million||-6.07|
|Cogentix Medical Competitors||$2.01 billion||$429.46 million||-58.52|
Cogentix Medical’s peers have higher revenue and earnings than Cogentix Medical. Cogentix Medical is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Cogentix Medical peers beat Cogentix Medical on 5 of the 9 factors compared.
Cogentix Medical Company Profile
Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.
Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.